Libtayo
Sanofi’s Libtayo shows positive Phase III results in advanced cervical cancer
May 13, 2021Libtayo, Sanofi, cemiplimab, cervical cancer
Regeneron Pharmaceuticals and Sanofi have announced today positive Phase III trial results investigating the PD-1 inhibitor Libtayo (cemiplimab) in patients …
Phase III trial of Libtayo stopped early after positive overall survival results
March 15, 2021Sales and Marketing Cancer, Libtayo, Regeneron, Sanofi
A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) will be stopped early after positive results demonstrated …
Promising Phase 2 data for Sanofi and Regeneron’s PD-1 inhibitor Libtayo in locally advanced basal cell carcinoma
September 18, 2020Medical Communications, Research and Development Cancer, ESMO 2020, Libtayo, Regeneron, Sanofi, pharma
Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi …
Sanofi and Regeneron’s Libtayo shows durable responses in world’s most common skin cancer
May 5, 2020Manufacturing and Production, Research and Development Cancer, Libtayo, Regeneron, Sanofi
Sanofi and Regeneron’s have lifted the lid on new topline data on their PD-1 inhibitor Libtayo (cemiplimab) in patients with …
Phase 3 Libtayo monotherapy trial halted early due to strong benefit in advanced non-small cell lung cancer
April 29, 2020Research and Development Cancer, Libtayo, Regeneron, Sanofi, lung cancer
A Phase 3 study of Sanofi and Regeneron’s Libtayo (cemiplimab) as a monotherapy for advanced or metastatic non-small cell lung …
Sanofi and Regeneron’s Libtayo approved on NHS Scotland for cutaneous squamous cell carcinoma
February 11, 2020Manufacturing and Production, Sales and Marketing Libtayo, NHS, Regeneron, Sanofi, Scotland, nhs scotland, pharma
Scottish patients will now be able to access Sanofi and Regeneron’s Libtayo (cemiplimab) via the NHS after it became known …
Libtayo becomes first EU-approved therapy for advanced cutaneous squamous cell carcinoma
July 2, 2019Manufacturing and Production, Sales and Marketing Europe, Libtayo, Regeneron, Sanofi, carcinoma, pharma
The European Commission has revealed that it has decided to award approval, albeit conditionally, to Sanofi and Regeneron’s Libtayo (cemiplimab) …
Latest content
